login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
PROMIS NEUROSCIENCES INC (PMN) Stock News
USA
- NASDAQ:PMN -
CA74346M4065
-
Common Stock
0.5279
USD
+0.03 (+6%)
Last: 10/6/2025, 9:32:45 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
PMN Latest News, Press Relases and Analysis
All
Press Releases
a month ago - By: Benzinga
- Mentions:
MEIP
IMCC
SSKN
GNPX
...
12 Health Care Stocks Moving In Friday's After-Market Session
a month ago - By: Benzinga
- Mentions:
NBY
PHR
IMCC
MODD
...
12 Health Care Stocks Moving In Friday's Pre-Market Session
a month ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
a month ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
2 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
2 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
2 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
2 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
2 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces Private Placement Financing
2 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces Private Placement Financing
3 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces Private Placement Financing
3 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces Private Placement Financing
3 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules
3 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease
4 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
5 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces First Quarter 2025 Financial Results
5 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces First Quarter 2025 Financial Results
6 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
6 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
7 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference
7 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference
7 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting
Please enable JavaScript to continue using this application.